Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2025-01-08 00:00:00 ET · period of report 2025-01-06 · accession 0001714899-25-000049 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-01-08 | 2025-01-06+ | DNLI | Watts Ryan J. | Pres, CEO, Dir | S - Sale | $20.34 | -36.9K | 253.1K | -13% | -$751.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-06 | S | D | 29,266 | $20.22 | 260,721 | D | — | — | (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.91 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 177,940 Unvested RSUs. |
| 2 | Common | Common Stock | 2025-01-07 | S | D | 7,650 | $20.81 | 253,071 | D | — | — | (F3) Includes 177,940 Unvested RSUs. |